Brief: Windtree Therapeutics Positive Topline Results From Phase 2B Seismic Extension Study Of Istaroxime In Early Cardiogenic Shock
25/09/2024 13:11
Sept 25 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE THERAPEUTICS: POSITIVE TOPLINE RESULTS FROM PHASE
2B
SEISMIC EXTENSION STUDY OF ISTAROXIME IN EARLY CARDIOGENIC SHOCK
* WINDTREE THERAPEUTICS INC: ISTAROXIME SIGNIFICANTLY
IMPROVED
PRIMARY ENDPOINT OF SYSTOLIC BLOOD PRESSURE PROFILE OVER SIX
HOURS
* WINDTREE THERAPEUTICS INC: ISTAROXIME SHOWED SIGNIFICANT
IMPROVEMENTS IN MANY SECONDARY ENDPOINT ASSESSMENTS
* WINDTREE THERAPEUTICS INC: SAFETY PROFILE WAS FAVORABLE
AND
GENERALLY CONSISTENT IN ISTAROXIME STUDY
Source text for Eikon: ID:n0001437749-24-029936
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study